Abstract
Malignant pleural mesothelioma (MPM) is a rare but highly aggressive tumor of pleura arising in response to asbestos fibers exposure. MPM is frequently diagnosed in the advanced stage of the disease and causes poor prognostic outcomes. From the clinical perspective, MPM is resistant to conventional treatment, thus challenging the therapeutic options. There is still demand for improvement and sensitization of MPM cells to therapy in light of intensive clinical studies on chemotherapeutic drugs, including immuno-modulatory and targeted therapies. One way is looking for natural sources, whole plants, and extracts whose ingredients, especially polyphenols, have potential anticancer properties. This comprehensive review summarizes the current studies on natural compounds and plant extracts in developing new treatment strategies for MPM.
Highlights
Malignant pleural mesothelioma (MPM) is a relatively rare tumor of pleura arising in approximately 80% of cases due to prolonged occupational exposure to asbestos fibers in the past
[39,40], was one of the first compounds recancer treatment since the excessive generation of reactive oxygen species (ROS) leads to the breakdown of DNA, ported to cell cause mesothelioma direct stimulation of cell inhibiting growth and death.cell
The discussed above studies confirm the potential anticancer activity of polyphenols and other natural compounds that can directly induce apoptosis of mesothelioma cells and increase MPM cells’ sensitivity to chemotherapy
Summary
Malignant pleural mesothelioma (MPM) is a relatively rare tumor of pleura arising in approximately 80% of cases due to prolonged occupational (rarely environmental or domestic) exposure to asbestos fibers in the past. In many European countries, the incidences of mesothelioma result from a prolonged latency period between asbestos exposure (starting in the 1970s) and cancer diagnosis [3]. This particular cancer type is highly aggressive and insensitive to conventional treatment, including radiotherapy, resection (in justified cases), and primary chemotherapy. New targeted strategies and immunotherapies, especially immune checkpoint inhibitors, are under intensive investigation for patients who are not candidates for cisplatin-based therapy. This review sheds light on the current state of research on phytochemicals investigated in MPM therapy
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
